The Europe Microtome Market would witness market growth of 5.7% CAGR during the forecast period (2022-2028).
The increased prevalence of chronic diseases, the growing senior population, and rising healthcare expenditures, particularly in industrialized nations, are driving this trend. One of the primary elements expected to enhance development is the increasing commercial availability of high-quality diagnostic technology in developed nations, which account for the majority of revenue. Despite this, there is an unmet demand for technologically improved diagnostic equipment in poor countries due to lower per capita disposable income and limited commercial availability.
According to estimates, 4 million new cancer cases (excluding non-melanoma skin cancer) and 1.9 million cancer-related deaths occur each year. Breast cancer in women (530,000), colorectum (520,000 cases), lung (480,000 cases), and prostate cancer (480,000) are the most frequent cancers (470,000). These four tumors represent half of Europe's total cancer burden. Lung (380,000), colorectal (250,000), breast (140,000), and pancreatic (130,000) malignancies are the most common causes of cancer mortality. There are around 1.4 million new cancer cases in males and 1.2 million new cancer cases in females in the EU-27, with over 710,000 estimated cancer deaths in males and 560,000 projected cancer deaths in females.
The United Kingdom has long been a leader in cancer diagnostic research and therapy development. It has a robust cancer diagnostics and treatment sector and continues to play a key role in cancer early detection, drastically improving patient survival rates around the world. In the United Kingdom, one in every two people will be diagnosed with cancer at some point in their lives. Every day, the NHS in the United Kingdom identifies 980 cancer cases. Cancer Research UK, the world's largest independent cancer charity, is based in the United Kingdom and spends around £385 million each year supporting 4,000 researchers in 90 institutions around the country.
The Germany market dominated the Europe Microtome Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $38.1 million by 2028. The UK market is poised to grow at a CAGR of 4.8% during (2022 - 2028). Additionally, The France market would display a CAGR of 6.5% during (2022 - 2028).
Based on Product, the market is segmented into Instruments (Rotary, Cryostat, Vibrating, and Others) and Accessories. Based on Technology, the market is segmented into Fully Automated, Semi-automated, and Manual. Based on Application, the market is segmented into Disease Diagnosis and Medical Research. Based on End-user, the market is segmented into Hospital Laboratories, Clinical Laboratories, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Microtome Market will Hit $605.5 Million by 2028, at a CAGR of 6.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Danaher Corporation, Cardinal Health, Inc., PHC Holdings Corporation, Boeckeler Instruments, Inc., Bright Instruments Limited, Erma, Inc., Histo-line Laboratories, microTec Laborgeräte GmbH, MEDITE Medical GmbH, and Sakura Finetek USA, Inc.
By Product
By Technology
By Application
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 